RecruitingNot ApplicableNCT07782944

CD38 Targeted -PET/ CT for Multiple Myeloma

Clinical Investigation of CD38-Targeted Molecular Imaging Probes in Multiple Myeloma

Sponsor

Guilin Medical University, China

Enrollment

100 participants

Start Date

Jul 7, 2026

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Summary

The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying standard-of-care imaging (FDG PET/CT), CD38 PET/CT for people with multiple myeloma (mm), lymphoma, large b-cell, diffuse (dlbcl), lymphoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTstandard-of-care imaging (FDG PET/CT), CD38 PET/CT

Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (FDG) and CD38, and undergoes PET/CT imaging within the specified time.

Locations(1)

The First Affliated Hospital of Guilin Medical University

Guilin, Guangxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07782944

Related Trials

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

NCT074104941 location

Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies

NCT072702631 location

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

NCT073094972 locations

Randomised Controlled Trial of Artificial Intelligence-assisted Health Education

NCT073053371 location